Clinical and Virologie Efficacy of Herpes Simplex Virus Type 2 Suppression by Acyclovir in a Multicontinent Clinical Trial

Journal of Infectious Diseases

Volumn 201, Issue 8, 2010, Pages 1164-1168

  Fuchs, Jonathan ^a,b   Celum, Connie ^c   Wang, Jing ^e   Hughes, James ^d   Sanchez, Jorge ^g   Cowan, Frances ^h   Reid, Stewart ^f,i   Delany Moretlwe, Sinead ^j   Corey, Lawrence ^c,d,e   Wald, Anna ^c,d,e  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Global Health ^*  (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f University of Alabama at Birmingham   (United States)

^g Asociación Civil Salud y Educación   (United States)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁱ Centre for Infectious Disease Research   (Zambia)

^j UNIVERSITY OF THE WITWATERSRAND   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; PLACEBO; VIRUS DNA; ANTIVIRUS AGENT;

AFRICA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENITAL HERPES; GENITAL ULCER; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PATIENT COMPLIANCE; PERU; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNITED STATES; DRUG EFFECT; MULTICENTER STUDY; SOUTH AFRICA; VIRUS SHEDDING; ZAMBIA; ZIMBABWE;

ACYCLOVIR; ANTIVIRAL AGENTS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HUMANS; MALE; PERU; SOUTH AFRICA; UNITED STATES; VIRUS SHEDDING; ZAMBIA; ZIMBABWE;

EID: 77950292824     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651381     Document Type: Article

References (15)

1. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 in-fection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006;20: 73-83.
2. Zhu J, Hladlik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009;15: 886-892.
3. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomized, double-blind, placebo controlled trial. Lancet 2008;371: 2109-2119.
4. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008;358: 1560-1571.
5. Jerome K, Huang M, Wald A, et al. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol 2002;40: 2609-2611.
6. Corey L, Huang ML, Selke S, Wald A. Differentiation of herpes simplex virus 1 and 2 in clinical samples by a real-time Taqman PCR assay. J Med Virol 2005;76: 350-355.
7. Magaret A, Wald A, Huang ML, et al. Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J Clin Microbiol 2007;45: 1618-1620.
8. Douglas JM, Critchlow C, Benedetti J, et al. A double blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984;310: 1551-1556.
9. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of sub-clinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124: 8-15.
10. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for sup-pression of shedding of herpes simplex virus in the genital tract. J In-fect Dis 2004;190: 1374-1381.
11. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-l/HSV-2-seropositive men: a randomized, doubleblind, placebo-controlled crossover trial. J Infect Dis 2007;196: 1500-1508.
12. Cowan FM, Pascoe SJ, Barlow KL, et al. A randomised placebo-con-trolled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect 2008;84: 548-553.
13. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of an-tiviral therapy. Clin Microbiol Rev 2003;16: 114-128.
14. Norberg P, Kasubi MJ, Haarr L, et al. Divergence and recombination of clinical herpes simplex virus type 2 isolates. J Virol 2007;81: 13158-13167.
15. Berg K, Arnsten J. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr 2006;43: S79-S87.